Endo, other drugmakers sued over ‘pay-for-delay’ deals
The Federal Trade Commission sued Endo Pharmaceuticals and several other drugmakers alleging that they used ‘pay-for-delay’ settlements to block consumers’ access to lower-cost generic versions of Opana ER and Lidoderm....
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information: